×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRK – merck & company, inc. (new) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
11:51 am
mrk
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]
Low
Report
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]
1/15
09:09 am
mrk
Is Merck Stock A Trap At $110? [Forbes]
Low
Report
Is Merck Stock A Trap At $110? [Forbes]
1/15
07:30 am
mrk
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]
Low
Report
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]
1/15
07:27 am
mrk
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]
Low
Report
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]
1/14
11:11 am
mrk
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]
Low
Report
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]
1/14
09:21 am
mrk
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Yahoo! Finance]
Low
Report
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Yahoo! Finance]
1/13
07:07 pm
mrk
7MM Insomnia Market Opportunity Assessment and Forecast Report 2022-2025 & 2025-2032 [Yahoo! Finance]
Low
Report
7MM Insomnia Market Opportunity Assessment and Forecast Report 2022-2025 & 2025-2032 [Yahoo! Finance]
1/13
01:56 pm
mrk
Merck Lifts Long-Term Revenue Target [Yahoo! Finance]
Low
Report
Merck Lifts Long-Term Revenue Target [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
2.5%
merck & company, inc. (new)
7/29/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
-5.0%
merck & company, inc. (new)
4/24/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
0.8%
merck & company, inc. (new)
2/4/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
-9.7%
merck & company, inc. (new)
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/5
12:23 pm
mrk
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Seidman Christine E
Low
Report
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Seidman Christine E
1/5
12:21 pm
mrk
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: GLOCER THOMAS H
Low
Report
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: GLOCER THOMAS H
1/5
12:17 pm
mrk
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Coe Mary Ellen
Low
Report
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Coe Mary Ellen
12/4
04:36 pm
mrk
Form 8-K Merck & Co., Inc. For: Dec 04
Low
Report
Form 8-K Merck & Co., Inc. For: Dec 04
12/2
06:03 am
mrk
Form FWP Merck & Co., Inc. Filed by: Merck & Co., Inc.
Low
Report
Form FWP Merck & Co., Inc. Filed by: Merck & Co., Inc.
11/12
04:12 pm
mrk
Form 13F-HR Merck & Co., Inc. For: Sep 30
Low
Report
Form 13F-HR Merck & Co., Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
TOP News Decliners
3/13
Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily]
-8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: